Trim 10-15% at $161.61 to monetize gains; negative risk/reward with RSI 62.98 and 10-15% rally in 12 sessions
Underweight maintained with 10-15% trim executed at stretched levels ($161.61). The 9/28 empirical validation (-1.2% alpha from Hold at $158) confirms trim is superior to pure Hold when setup is extended with negative risk/reward (1.7:1 actual: 5.2% upside to $170 vs 3.0% downside to $156.69). Position stays core (85-90%) with structural defenses intact; re-engage on pullback to $153-155 or confirmed breakout above $162.13. Avoids forfeiture of gains while maintaining quality exposure through binary event risk within 4 weeks.
| Position | Action |
|---|---|
| Price at $160-162 with volume >2.5M and follow-through | Trim 10-15% of position to monetize gains |
| Confirmed daily close above $162.13 on volume >4M with MACD expanding and RSI through 60 | Add 25-33% of position size with stop at breakout level |
| $153-155 pullback zone (50 SMA/lower BB confluence) on closing basis with MACD histogram positive and RSI cooling toward 50-55 | Re-engage/add to position |
Emerson's transformation into a pure-play industrial automation leader is delivering accelerating earnings growth with best-in-class FCF margins, creating a compelling risk/reward at 22.3x forward P/E with a ramping buyback program and no negative catalysts in the tape.
| Indicator | Value | Signal |
|---|---|---|
| Close (10/02) | $161.61 | bullish |
| 10 EMA | $156.69 | bullish |
| 50 SMA | $154.49 | bullish |
| 200 SMA | $143.82 | bullish |
| RSI (14) | 62.98 | bullish |
| MACD | 1.78 | bullish |
| MACD Signal | 0.79 | bullish |
| MACD Histogram | +1.00 | bullish |
| Bollinger Upper Band | $162.13 | neutral |
| Bollinger Middle Band (20 SMA) | $153.06 | neutral |
| Bollinger Lower Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed daily close above $162.13 on volume >4M with MACD expanding and RSI through 60
Then: Add 25-33% of position size with stop at breakout level
↩ rebuts: “Bear concern that TTM P/E of 35.5x makes EMR expensive”
EV: +$3.39 to $8.39 (from $161.61 to target of $165-170) · concedes: EMR is not a deep value play at 22x forward earnings — it's a quality compounder priced at a quality compounder's multiple; Slightly above-market beta of 1.21 means higher volatility is the price of admission; Upper Bollinger Band resistance at $162.13 is a real technical hurdle; TTM P/E of 35.5x is legitimately elevated; 2002-era 10-year yields are a real macro headwind for the broad industrial sector
EMR's premium valuation is built on consensus estimates that imply 59% earnings growth, a comp effect rather than secular acceleration, and an unsustainable multiple at 22.3x when the macro backdrop is deteriorating with highest-in-generation yields and a stock pressing against technical resistance at the upper Bollinger Band.
· concedes: FCF generation is real; Deleveraging is real; Operational quality is real; EMR is not a broken company
→ vs conservative: The conservative 'wait for pullback to $153-155' is leaving too much return on the table; TTM P/E of 35.5x is analytically backwards when forward P/E is 22.3x and earnings growing 20% with margin expansion
→ vs conservative: 10-year yields at 2002 highs are a headwind for multiples but not for demand when geopolitical drivers override economic cycles; energy capex is the counter-cyclical buffer being ignored
→ vs neutral: 'Wait for dovish Fed signal or confirmed FY2026 beat-and-raise' is a recipe for buying 8% higher after the print; the point is to position before the catalyst, not after
→ vs conservative: Negative tangible book value at negative $6.4 billion is a value-investor disqualifier but irrelevant for momentum-and-quality investors; AspenTech and National Instruments are category-leading software platforms with high renewal rates
| $143.98 |
| bullish |
| ATR (14) | $3.96 | neutral |
Support: 143.82 · 143.98 · 153.06 · 156.69 | Resistance: 162.13 · 165 · 170
The technical analysis presents a constructively bullish outlook for EMR, with all three moving averages in perfect bullish alignment (Price > 10 EMA > 50 SMA > 200 SMA) and the 200 SMA confirming intact long-term trend. Momentum indicators are bullish with MACD line above signal and expanding positive histogram, while RSI at 62.98 indicates constructive but not yet overbought conditions. Key near-term resistance sits at $162.13 (upper Bollinger Band) with strong support confluence at $143.82-$143.98 (200 SMA / lower Bollinger Band alignment). The report recommends HOLD with a bullish bias, suggesting existing holders maintain positions with trailing stops near the 10 EMA while new entrants await either a confirmed breakout above $162.13 or a pullback entry to the $153-$156 support zone.
Market Cap
$90.55B
Current Price
$162.34
P/E Ratio (TTM)
35.5x
Forward P/E
22.3x
PEG Ratio
1.86
Price / Book
4.44x
EPS (TTM)
$4.57
Forward EPS
$7.27
Dividend Yield
1.37%
Beta
1.21
52-Week High
$166.35
52-Week Low
$122.64
50-Day MA
$154.65
200-Day MA
$144.62
Book Value / Share
$36.54
Gross Margin (TTM)
53.2%
Operating Margin
26.9%
Profit Margin (Net)
13.8%
EBITDA
$6.06B
Return on Equity (ROE)
12.8%
Return on Assets (ROA)
6.9%
Revenue (TTM)
$18.64B
Revenue (Q4 2026)
$4.87B
Net Income (Q4 2026)
$718M
Diluted EPS (Q4 2026)
$1.28
Q4 2026 Gross Margin
54.5%
Total Assets
$42.21B
Cash & Equivalents
$2.18B
Goodwill + Intangibles
$26.81B
Total Debt
$13.26B
Net Debt
$10.93B
Stockholders' Equity
$20.38B
Working Capital
-$1.12B
Current Ratio
0.90
Debt to Equity (book)
0.65x
Net Debt / EBITDA
~1.8x
Tangible Book Value
-$6.43B
Retained Earnings
$41.6B
Operating Cash Flow (TTM)
~$4.14B
Free Cash Flow (TTM)
$3.71B
FCF Margin
19.9%
CapEx (TTM)
~$0.43B
FCF (Q4 2026)
$1.32B
Dividends (Quarterly)
$311-312M
Buybacks (Q4 2026)
$356M
Restructuring Charges (Q4 2026)
$128M
Annual Revenue FY2025
$18.02B
Annual Revenue FY2024
$17.49B
Annual Revenue FY2023
$15.17B
Annual Revenue FY2022
$13.80B
Annual Net Income FY2025
$2.29B
Annual Net Income FY2024
$1.97B
Annual Net Income FY2023
$13.22B
Strengths
Concerns
Emerson Electric is a transforming industrial automation pure-play with improving fundamentals including Q4 2026 revenue acceleration (+7.1% YoY), expanding gross margins (54.5%), and strong FCF generation ($3.71B TTM), while actively deleveraging and ramping up buybacks ($356M in Q4 2026). However, the stock trades near its 52-week high at a rich 35.5x TTM P/E with negative tangible book value (-$6.43B) and 63% of assets in goodwill/intangibles, creating balance sheet risk and limiting deep-value appeal.
Macro: Hawkish-rate regime with 10Y Treasury at highest since 2002 (biggest monthly gain since 2022), 30Y also at 2002 highs, mortgage rates at 7.58% approaching 3-year peak; Fed chorus signaling more work to do on inflation; Polymarket pricing 96% odds of zero Fed cuts in 2026 ($8.8M volume); US recession odds only 8%; cooler-than-expected inflation print triggered tech rally; September jobs report missed expectations; Iran war pushing inflation higher via non-oil channels; Nasdaq/Nvidia at record highs while Dow and S&P 500 posted monthly September losses; small caps struggling; oil prices falling into early October despite Iran tensions.